Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Calidi Biotherapeutics Inc. (CLDI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CLDI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -56.44% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.11M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 1.06 | 52 Weeks Range 0.20 - 3.89 | Updated Date 06/30/2025 |
52 Weeks Range 0.20 - 3.89 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -111.74% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1256000 | Price to Sales(TTM) 50.83 |
Enterprise Value 1256000 | Price to Sales(TTM) 50.83 | ||
Enterprise Value to Revenue 49.42 | Enterprise Value to EBITDA -1.64 | Shares Outstanding 31792600 | Shares Floating 27053448 |
Shares Outstanding 31792600 | Shares Floating 27053448 | ||
Percent Insiders 6.81 | Percent Institutions 17.24 |
Analyst Ratings
Rating 1 | Target Price 10 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Calidi Biotherapeutics Inc.
Company Overview
History and Background
Calidi Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncolytic virotherapy platforms for cancer treatment. Founded with the goal of harnessing the power of the body's immune system to fight cancer. The company's initial focus was on the development of stem cell-based delivery systems for oncolytic viruses.
Core Business Areas
- Oncolytic Virotherapy: Development of oncolytic viruses that selectively infect and kill cancer cells while stimulating an anti-tumor immune response.
- Stem Cell Delivery: Utilizing stem cells as a delivery mechanism to protect and deliver oncolytic viruses to tumors.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its oncolytic virotherapy candidates in various cancer types.
Leadership and Structure
The leadership team consists of experienced executives and scientists with expertise in oncology, virology, and drug development. The organizational structure is based on departments focused on research, clinical development, manufacturing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Vesigenurtacel-L (CLD-101): An oncolytic vaccinia virus delivered using neural stem cells. Currently in clinical development for advanced solid tumors. Market share data is not yet available as it's in clinical trials. Competitors include companies developing oncolytic viruses, such as Amgen (Imlygic) and Replimune.
- CLD-201: An oncolytic adenovirus armed with a transgene. Preclinical. Market share is not applicable at this stage. Competitors: Companies developing gene therapies and viral vectors for cancer treatment (e.g., bluebird bio, Novartis).
Market Dynamics
Industry Overview
The oncology market is rapidly growing, with increasing demand for novel and targeted therapies. Oncolytic virotherapy is an emerging field with potential to improve cancer treatment outcomes.
Positioning
Calidi Biotherapeutics is positioned as an innovator in the oncolytic virotherapy space, with a focus on developing novel delivery systems and armed oncolytic viruses. Competitive advantages include its proprietary stem cell delivery platform and promising preclinical and clinical data.
Total Addressable Market (TAM)
The global oncology market is estimated at hundreds of billions of dollars annually. Calidi is focusing on specific cancer types, and the TAM for oncolytic virotherapy is significant, estimated to be in the billions of dollars. Their position is dependent on positive clinical trial data and successful commercialization.
Upturn SWOT Analysis
Strengths
- Novel stem cell delivery platform
- Promising preclinical and clinical data
- Experienced leadership team
- Proprietary technology
Weaknesses
- Early-stage clinical development
- Limited financial resources
- High risk of clinical trial failure
- Reliance on partnerships
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new cancer indications
- Positive clinical trial results
- Increasing market demand for oncolytic virotherapy
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- AMGN
- RPIM
- BNTX
Competitive Landscape
Calidi has the advantage of neural stem cell delivery. Disadvantages may include clinical data and funding compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: N/A
Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and commercialization success. Analyst estimates vary, but projections are based on the potential of its oncolytic virotherapy platform.
Recent Initiatives: Focus on advancing clinical trials for CLD-101 and developing new oncolytic virus candidates.
Summary
Calidi Biotherapeutics is an early-stage company with novel oncolytic virotherapy. Its strength lies in the stem cell delivery platform, however it faces challenges with funding and clinical trial success. Positive trial results are key to future growth. They must compete against larger, established pharmaceutical companies which is a concern.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Calidi Biotherapeutics website
- SEC filings
- Industry reports
- Clinical trial data
- Market research reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The biotechnology industry is inherently risky, and investments may result in losses.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Calidi Biotherapeutics Inc.
Exchange NYSE MKT | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-11-01 | CEO & Director Dr. Eric E. Poma Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://www.calidibio.com |
Full time employees 28 | Website https://www.calidibio.com | ||
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors. The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.